Troy Groetken Featured in Generics Bulletin Article “How Can Firms Avoid Falling Into GSK-Teva ‘Skinny Label’ Trap?”


Troy noted that “while future decisions may clarify the impact of the GSK-Teva ruling, for now firms with ‘skinny label’ generics will have to plan carefully to avoid potential induced-infringement allegations.” The article covers key issues on the topic and discusses other potential implications of GSK-Teva.

Read the complete article here. (Subscription may be required)